SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.
$BBOT
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/5/2025 | $20.00 | Overweight | Morgan Stanley |
| 9/17/2025 | $25.00 | Outperform | Leerink Partners |
| 9/15/2025 | $27.00 | Buy | H.C. Wainwright |
| 8/15/2025 | $21.00 | Overweight | Piper Sandler |
SCHEDULE 13G/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)
SCHEDULE 13G/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)
10-Q - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
Morgan Stanley initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $20.00
Leerink Partners initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $25.00
H.C. Wainwright initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $27.00
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT's 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in November 2025. The employee received non-qualified stock options to purchase 53,060 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $12.88 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the f
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy and in combination with standard of care therapies in mutant or wild-type PIK3CA breast cancer modelsBBOT will also present a trial in progress poster on BREAKER-101, a Phase 1 clinical trial evaluating BBO-10203 in patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer with initial Phase 1 data expected in the first half of 2026 SOUTH SAN FRANCISCO, Calif., Dec. 10, 2
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in December. Details of the company's participation are as follows: Piper Sandler 37th Annual Healthcare ConferencePresentation: Tuesday, December 2, at 2:00 p.m. ET 8th Annual Evercore Healthcare ConferencePresentation: Wednesday, December 3, at 9:35 a.m. ET Live webcasts of the presentations will be accessible on the "Events" page of the BBOT website at https://investors.bbotx.co
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar